Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Sumagen Ebola vaccine
- Development stage
- Preclinical
- Lead developer
- Merck
- Modality
- Viral Vector Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
Sumagen Canada is developing a viral vector vaccine for the prevention of Ebola virus disease. The vaccine utilizes a recombinant Vesicular Stomatitis Virus (rVSV) platform to create pseudotyped virions that display both the VSV glycoprotein and the Ebola virus glycoprotein (GP) on their surface. By delivering the gene encoding the Ebola GP, the vaccine triggers the host's immune system to produce neutralizing antibodies and activate T-cell responses against the Ebola virus. This dual-glycoprotein display is intended to enhance the immunogenicity and stability of the vaccine candidate. Currently in the research and development stage, this candidate aims to provide a robust prophylactic option against Ebola virus infections.
- Other names
- Sumagen Canada-Ebola glycoprotein-viral vector vaccine-Ebola virus diseaseVSV-based Ebola VaccinerVSV pseudotype Ebola vaccine
02
Targets
Zaire ebolavirus glycoprotein
Beyond the preview
Go deeper on Sumagen Ebola vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Sumagen Ebola vaccine.